The fallacies of the lipid hypothesis

Scandinavian Cardiovascular Journal

Volumn 42, Issue 4, 2008, Pages 236-239

  Ravnskov, Uffe ^a  

^a Magle Stora Kyrkogata 9   (Sweden)

Author keywords

Cardiovascular disease; Cholesterol; Saturated fat

Indexed keywords

CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIPID; SATURATED FATTY ACID; STATIN;

ABORTION; AMNESIA; BIRTH DEFECT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; DEPRESSION; HEALTH CARE; HUMAN; IMPOTENCE; KIDNEY FAILURE; LIVER INJURY; MEDICAL RESEARCH; MUSCLE DISEASE; NERVE INJURY; PRIORITY JOURNAL;

ATHEROSCLEROSIS; CHOLESTEROL, LDL; CORONARY DISEASE; FATTY ACIDS; HUMANS;

EID: 48349126794     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/14017430801983082     Document Type: Conference Paper

References (26)

1. Ravnskov U. The questionable role of saturated and polyunsaturated fatty acids in cardiovascular disease. J Clin Epidemiol. 1998;51:443-60.
2. Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT. Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. Am J Clin Nutr. 2006;83:1025-31.
3. Ravnskov U. The Cholesterol Myths. Washington: New Trends Publishing; 2000.
4. Roselli della Rovere G, Lapolla A, Sartore G, Rossetti C, Zambon S, Minicuci N, et al. Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr Metab Cardiovasc Dis. 2003;13:46-51.
5. Bellomo G, Lippi G, Saronio P, Reboldi G, Verdura C, Timio F, et al. Inflammation, infection and cardiovascular events in chronic hemodialysis patients: a prospective study. J Nephrol. 2003;16:245-51.
6. Ravnskov U. High cholesterol may protect against infections and atherosclerosis. Q J Med. 2003;96:927-34.
7. Ravnskov U. Is atherosclerosis caused by high cholesterol. Q J Med. 2002;95:397-403.
8. Mölgaard J, von Schenk H, Kuusi T, Holme I, Lassvik C, Taskinen MR, et al. Plasma lipoprotein abnormalities and apolipoptotein E phenotypes in intermittent claudication. A multivariate analysis of randomly selected subjects. Nutr Metab Cardiovasc Dis. 1996;6:114-23.
9. Miettinen TA, Gylling H. Mortality and cholesterol metabolism in familial hypercholesterolemia. Arteriosclerosis. 1988;8:163-7.
10. Neil HAW, Seagroatt V, Betteridge DJ, Cooper MP, Durrington PN, Miller JP, et al. Established and emerging coronary risk factors in patients with heterozygous familial. hypercholesterolaemia. Heart. 2004;90:1431-7.
11. Rodriguez G, Bertolini S, Nobili F, Arrigo A, Masturzo P, Elicio N, et al. Regional cerebral blood flow in familial hypercholesterolaemia. Stroke. 1994;25:831-6.
12. Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SC. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2001;87:547-53.
13. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Ann Rev Biochem. 1983;52:223-61.
14. Jansen AC, van Aalst-Cohen ES, Tanck MW, Cheng S, Fontecha MR, Li J, et al. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2005;25:1475-81.
15. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ. 1992;305:15-9.
16. Ravnskov U, Rosch PJ, Sutter MC, Houston MC. Should we lower cholesterol as much as possible? BMJ. 2006;332:1330-2.
17. Solomon H, Samarasinghe YP, Feher MD, Man J, Rivas-Toro H, Lumb PJ, et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract. 2006;60:141-5.
18. Kenis I, Tartakover-Matalon S, Cherepnin N, Drucker L, Fishman A, Pomeranz M, et al. Simvastatin has deleterious effects on human first trimester placental explants. Hum Reprod. 2005;20:2866-72.
19. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med. 2004;350:1579-82.
20. Marzoa-Rivas R, Crespo-Leiro MG, Paniagua-Marin MJ, Llinares-Garcia D, Muniz-Garcia J, Aldama-Lopez G, et al. Safety of statins when response is carefully monitored: a study of 336 heart recipients. Transplant Proc. 2005;37:4071-3.
21. Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors. 2005;25:147-52.
22. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004;57:525-8.
23. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation. 1992;86:1046-60.
24. Sijbrands EJG, Westendorp RGJ, Defesche JD, de Meier PHEM, Smelt AHM, Kastelein JJP. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. Br Med J. 2001;322:1019-23.
25. Neil HAW, Hawkins MM, Durrington PN, Betteridge DJ, Capps NE, Humphries SE; Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis. 2005;179:293-7.
26. Ravnskov U. Quotation bias in reviews of the diet-heart idea. J Clin Epidemiol. 1995;48:713-9.